| SARS–CoV‐2 infection and COVID‐19 outcomes in rheumatic diseases: a systematic literature review and meta‐analysis R Conway, AA Grimshaw, MF Konig, M Putman, A Duarte‐García, ... Arthritis & Rheumatology 74 (5), 766-775, 2022 | 132 | 2022 |
| Safety and efficacy of anti-interleukin-1 treatment in 40 patients, followed in a single centre, with AA amyloidosis secondary to familial Mediterranean fever S Ugurlu, B Ergezen, BH Egeli, O Selvi, H Ozdogan Rheumatology 59 (12), 3892-3899, 2020 | 31 | 2020 |
| Anakinra treatment in patients with familial Mediterranean fever: a single-centre experience S Ugurlu, B Ergezen, BH Egeli, O Selvi, H Ozdogan Rheumatology 60 (5), 2327-2332, 2021 | 19 | 2021 |
| Effects of vitamin supplements on clinical cardiovascular outcomes: Time to move on!–A comprehensive review B Simsek, A Selte, BH Egeli, U Çakatay Clinical Nutrition ESPEN 42, 1-14, 2021 | 9 | 2021 |
| Late-onset familial Mediterranean fever: single-center experience and literature review O Aydin, BH Egeli, H Ozdogan, S Ugurlu Internal and Emergency Medicine 17 (5), 1301-1306, 2022 | 8 | 2022 |
| Familial Mediterranean fever: clinical state of the art BH Egeli, S Ugurlu QJM: An International Journal of Medicine 115 (11), 711-718, 2022 | 7 | 2022 |
| Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain? BH Egeli, JA Sparks, AHJ Kim, JW Liew Best Practice & Research Clinical Rheumatology 35 (1), 101658, 2021 | 7 | 2021 |
| Soluble TREM-1 levels in familial Mediterranean fever related AA-amyloidosis S Ugurlu, BH Egeli, IM Bolayirli, H Ozdogan Immunological Investigations 50 (2-3), 273-281, 2021 | 7 | 2021 |
| The prevalence of familial Mediterranean fever and Behcet’s disease: a cross-sectional study Ö Alparslan, BH Egeli, Y Demirel, S Uğurlu Archives of Rheumatology 35 (4), 609, 2020 | 7 | 2020 |
| Features predicting colchicine efficacy in treatment of children with undefined systemic autoinflammatory disease: a retrospective cohort study MC Marques, BH Egeli, H Wobma, C Ribeiro, E Anderson, JS Hausmann, ... Diagn Interv Radiol 9 (9), 116-21, 2022 | 6 | 2022 |
| Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study BH Egeli, S Ergun, A Cetin, YK Gursoy, S Ugurlu Clinical Rheumatology 41 (1), 123-127, 2022 | 6 | 2022 |
| SARS-CoV-2 infection and COVID-19 outcomes in rheumatic disease: a systematic literature review and meta-analysis. Arthritis Rheumatol 74: 766–775 R Conway, AA Grimshaw, MF Konig, M Putman, A Duarte-García, ... | 5 | 2022 |
| The clinical role of anakinra in the armamentarium against familial Mediterranean fever K Parlar, MB Ates, BH Egeli, S Ugurlu Expert Review of Clinical Immunology 20 (5), 441-453, 2024 | 3 | 2024 |
| Patient perspectives on telemedicine use in rheumatology during the COVID-19 pandemic: Survey results from the COVID-19 Global Rheumatology Alliance M Maheswaranathan, B Miller, N Ung, R Sinha, C Harrison, BH Egeli, ... Clinical Rheumatology 43 (1), 543-552, 2024 | 1 | 2024 |
| A Rare Cause of AA Amyloidosis: Idiopathic Retroperitoneal Fibrosis S Ugurlu, BH Egeli, S Aslan, M Oztas, M Melikoglu JCR: Journal of Clinical Rheumatology 27 (8S), S685, 2021 | 1 | 2021 |
| Inflammatory hypothesis of atherogenesis: Will colchicine be added to the armamentarium in the prevention of coronary artery disease? B Simsek, BH Egeli, A Selte, B Varghese, RS Blumenthal, E Chew American Heart Journal Plus: Cardiology Research and Practice 9, 100057, 2021 | 1 | 2021 |
| POS1381 BIOLOGIC TREATMENT OF ADULT-ONSET STILL’S DISEASE: A SINGLE CENTER EXPERIENCE B Yurttas, B Egeli, GG Ozkose, S Ugurlu Annals of the Rheumatic Diseases 80 (Suppl 1), 974-974, 2021 | 1 | 2021 |
| Patient perceptions of telemedicine use in rheumatology clinics during the COVID-19 pandemic: an analysis from the COVID-19 global rheumatology Alliance M Maheswaranathan, B Miller, C Harrison, R Sinha, B Egeli, ... Arthritis & Rheumatology, 3994-3997, 2021 | 1 | 2021 |
| Comment on: Serum Strem-1 in adult-onset Still’s disease: a novel biomarker of disease activity and a potential predictor of the chronic course S Ugurlu, BH Egeli Rheumatology 59 (11), e115-e115, 2020 | 1 | 2020 |
| In Familial Mediterranean Fever, soluble TREM-1 plasma level is higher in case of amyloidosis S Ugurlu, BH Egeli Innate Immunity 26 (3), 231-231, 2020 | 1 | 2020 |
AYŞE HURİ ÖZDOĞANİstanbul üniversitesi, Cerrahpaşa tıp fakültesiVerified email at istanbul.edu.tr
